Simple Blood Test Maps Hidden Alzheimer’s Disease Changes

Here’s a breakdown of the key data⁣ from ⁣the provided text, focusing on ‍the study’s findings and methodology:

Core Study Focus:

* The study aimed to ‌determine how common alzheimer’s disease neuropathological changes (ADNCs) are ⁢in peopel aged 70⁤ and older.
* It used a blood test (measuring plasma phosphorylated tau at threonine ⁣217 – pTau217) as a way to estimate these changes,avoiding the need for more⁣ invasive or expensive tests like spinal fluid analysis or brain scans.

Key Findings:

* Age‍ is a major factor: ADNC prevalence increases considerably with age. It was under 8% in those aged 58-69.9 years, ⁢and nearly 65%​ in those over 90.
* cognitive Status Matters: The study examined the‍ relationship between‍ ADNC prevalence and cognitive status (cognitively normal,mild cognitive impairment (MCI),or dementia). (Specific ⁢prevalence rates for each cognitive group​ are not detailed​ in this excerpt, but the study investigated this.)
* ‌ APOE ε4 Gene: The study also looked at how ⁢the APOE ε4 gene‌ (a known risk factor for Alzheimer’s) relates to‌ ADNC ⁢prevalence.
* Kidney Function: kidney function‌ (measured by eGFR) was also examined for associations with ADNC.

Methodology:

* ⁣ Population: The study used data from ‌the Trøndelag Health (HUNT) studies ⁤in Norway, analyzing over 11,486 plasma samples.
* Age Groups: Included participants aged 58-69.9⁣ years and 70 years and older. Cognitive assessments were only done on the older group.
* ‍ Biomarker Measurement: Plasma ⁣pTau217 levels were ⁢measured using a specific platform (Simoa HD-X).
* ⁣ Classification: Participants were categorized into three⁤ groups based on⁢ pTau217 levels:
* ADNC-negative (<0.40 pg/mL)
​ * Intermediate (0.40 – <0.63 pg/mL)
‌ * ADNC-positive (≥0.63 pg/mL)
* Statistical Analysis: Researchers used statistical methods (inverse probability weighting) ⁣to account for potential biases in the data.‍ They also looked at predictive values and how the findings might relate to​ eligibility for Alzheimer’s treatments.

Implications:

* ‌ ⁤The study provides valuable data on the prevalence of ADNCs in the population.
* ‌ Blood biomarkers like pTau217 could be ⁣useful for identifying individuals who might benefit from further evaluation or disease-modifying therapies.
* The ⁢findings can definitely help with health service planning and individual decision-making regarding‌ Alzheimer’s risk.
* More research ⁢is needed to understand what to do with individuals who fall into the “intermediate” biomarker category.